Meningococcal meningitis in Africa: What's happened since the MenA CV introduction and when can we expect a licensed ACYWX conjugate vaccine

Meningitis Research Foundation, British Museum London, November 5, 2019


F Marc LaForce, Serum Institute of India Mark Alderson, PATH, Seattle







MenACV roll out as of October 2019



23 countries conducted mass campaigns + Eritrea planned Q4-2019 315+ million 1-29 year-olds vaccinated Dec 2010 - July 2019

10 countries introduced into routine

+ 4 planned in 2020 10+ million children vaccinated July 2016 - Dec 2018


No confirmed case of NmA in the meningitis belt in 2018-2019. Ongoing efforts to sustain the impact of campaigns through routine immunization

Suspected cases of meningitis and pathogens identified since 2010 in 15 countries (WHO surveillance data)

Year	Suspect cases	Nm A	Nm C	Nm Y	Nm W	Nm X
2010	30,103	439	4	0	726	55
2011	22,000	197	5	1	513	154
2012	28,805	88	4	1	1,009	138
2013	19,685	22	10	0	237	15
2014	21,641	5	48	1	286	11
2015	27,304	80*	1,224	0	545	20
2016	26,029	22*	375	6	719	68
2017	34103	2	891	2	263	333
2018	20,843	0	466	0	71	293
2019 (wk 26)	13,120	0	317	0	96	102

Epidémies de méningite 2019

countries	Suspected cases (2019)	Deaths (2019)
Burkina Faso	1 695	125 (CFR = 7.4%)
Chad	336	49 (CFR = 14.6%)
Тодо	213	7 (CFR = 3.3 %)
Ghana	746	20 (CFR = 2.7%)




<u>Figure A</u> : Recapitulative map of cumulative Meningitis attack rates : epidemic season 2018 w 1-26

<u>Figure B</u> : Recapitulative map of cumulative Meningitis attack rates : epidemic season 2019 w 1-26

Annual meeting of the International Coordinating Group on Vaccine Provision Geneva, 10-12 September 2019



Fractional distribution of African CSF isolates 2003-2019



Problem Statement

- Outbreaks due to serogroups C, W and X still occur, and have compelled reactive vaccination campaigns through the ICG system using polysaccharide and conjugate vaccines.
 - Licensed quadrivalent conjugate vaccines are expensive and don't cover serogroup X disease.
 - Despite reactive deployment of polysaccharide vaccines, many cases still occur and lives are lost to a vaccine-preventable disease.
 - Market incentives are lacking for suppliers of PS vaccines for the stockpile and current ICG stocks are insufficient.
- Proactive disease control is preferable if it is affordable.





To eliminate epidemic meningitis from sub-Saharan Africa through the development, testing, licensure, and introduction of a pentavalent (A, C, W, X, Y), heatstable meningococcal conjugate vaccine.



NmCV-5 Composition

Composition	Qty
Men A PS-TT	5 μg/ Dose
Men C PS-CRM	5 μg/ Dose
Men Y PS-CRM	5 μg/ Dose
Men W PS-CRM	5 μg/ Dose
Men X PS-TT	5 μg/ Dose
Sucrose	15 mg/vial
Sodium citrate	2.5 mg/vial
Tris buffer	0.61 mg/vial

Diluent	Sodium chloride in WFI (0.9% w/v)
Preservative	None*

Vaccine Presentations : Single Dose, 5 Dose

* WHO PSPQ recommendation in place

Overview of NmCV-5 clinical development plan

Phase (Study site)	Population	Primary objective	Status
Phase 1 (US)	18-45 years	Safety	Completed
Phase 2 (Africa)	12-16 months	Safety	Completed
Phase 3 (Africa)	2-29 years	Immunogenicity	Ongoing
Phase 3 (India)	18-85 years		Planned
Phase 3 (Africa)	9-15 months	Immunogenicity Non-interference with EPI vaccines	Planned

Phase 1 study design and results

- Double-blind, randomized, controlled study conducted at CVD, Baltimore.
- 60 adults (18-45 years) randomized to receive single IM dose of adjuvanted NmCV-5, non adjuvanted NmCV-5 or Menactra.
- Solicited reactions (until day 7), and unsolicited AEs (until day 28) including SAEs (throughput the study period of 168 days).
- Baseline and day 28 post vaccination bleeds for rSBA test (PHE, Manchester).

Study results

- All solicited reactions were either mild or moderate, and all of them resolved without sequelae.
- No related AEs in the NmCV-5 groups; no SAE reported during the study.
- Both the formulations of NmCV-5 showed similar and numerically higher GMTs for all five serogroups relative to Menactra.

Phase 1 - Day 28 rSBA GMTs

	NmCV-5 No adj. (N=20)		NmCV-5 +	AlPO4 (N=20)	Menactra (N=20)		
Serogroup	Pre	28 Days Post	Pre	28 Days Post	Pre	28 Days Post	
А	350 (119-1025)	5595 (3324-9418)	187 (50-708)	6889 (3767-12596)	33 (8.4-130)	3214 (1978-5222)	
C	4.3 (2.0-9.2)	6208 (3579-10771)	9.8 (3.8-26)	4096 (1720-9756)	68 (40-116)	410 (325-518)	
W	27 (6.2-117)	11191 (6720-18635)	8.0 (2.4-26)	8192 (3439-19513)	14 (4.2-47)	1261 (388-4091)	
X	5.3 (1.9-15)	1607 (892-2895)	6.3 (2.4-16)	1351 (577-3165)	3.4 (1.8-6.4)	3.1 (1.7-5.7)	
Y	24 (6.2-95)	9410 (4935-17942)	10 (3.0-34)	4545 (1700-12149)	54 (14-204)	2353 (1302-4251)	


- NmCV-5 elicited similar or somewhat better responses compared to Menactra for serogroups A, C, W and Y
- NmCV-5 elicited superior immune responses for Men X
- Adjuvanted and non-adjuvanted formulations of NmCV-5 were similar

Phase 2 study – African Toddlers

- Observer-blind, randomized, controlled study among toddlers aged 12-16 months at CVD, Bamako, Mali (routine MenAfriVac at 9 months not given).
- 375 toddlers randomized 2:2:1 to adjuvanted NmCV-5, non adjuvanted NmCV-5 or Menactra; 2 doses three months apart.
- Solicited reactions (until day 7), and unsolicited AEs (until day 28) after each dose, SAEs (throughout the study period of 84 days).
- Blood samples at baseline and day 28 post each vaccine dose for rSBA assessment.

Phase 2 study – Safety Results

- No participants reported any SAEs within 7 days of each vaccination.
- After the first vaccination the local and systemic solicited AEs ranged between 0.7% to 5.4% among all 3 groups.
- After the second vaccination there were few systemic solicited AEs.
- The majority of solicited adverse reactions were mild and all resolved uneventfully.
- There were three deaths during the study, one in each in group; none were deemed to be caused by the study products.



Proportion with 4-fold seroresponse in rSBA Titer with respect to Baseline - ACYWX-02, Toddlers, Mali

Phase 2 toddlers (Mali): % of subjects with rSBA ≥128 post dose 1

	Non-adjuvanted NmCV-5 (N=147)	Adjuvanted NmCV-5 (N=148)	Menactra (N=74)
Serogroup	(%) 95% Cl	(%) 95% CI	(%) 95% Cl
A	100 (97.5, 100)	100 (97.5, 100)	98.6 (92.7, 100)
С	98.6 (95.2, 99.8)	97.3 (93.2, 99.3)	54.1 (42.1, 65.7)
W	98.6 (95.2 <i>,</i> 99.8)	98.0 (94.2 <i>,</i> 99.6)	90.5 (81.5, 96.1)
Х	100 (97.5,100)	99.3 (96.3, 100)	20.3 (11.8, 31.2)
Y	97.3 (93.2, 99.3)	99.3 (96.3,100)	87.8 (78.2, 94.3)

Phase 2 Toddlers (Mali): rSBA GMTs

	NmCV-5 No adj. (n=144)			NmCV-5 +AlPO4 (n=144)			Menactra (n=72)		
Sero- group	Post Dose 1	Pre Dose 2	Post Dose 2	Post Dose 1	Pre Dose 2	Post Dose 2	Post Dose 1	Pre Dose 2	Post Dose 2
Α	7732 (6462- 9252)	4687 (3920- 5604)	6226 (5435- 7132)	7369 (6211- 8743)	4488 (3601- 5595)	6167 (5375- 7074)	3866 (1978- 5222)	2787 (2003- 3877)	4871 (3834- 6189)
С	<mark>1144</mark> (929- 1408)	437 (342-557)	1367 (1174- 1592)	1095 (878- 1367)	348 (273-445)	1393 (1201- 1617)	68 (40-116)	30 (19-47)	410 (325-518)
W	<mark>6533</mark> (4868- 8768)	2556 (1840- 3550)	8036 (6256- 10323)	5363 (3928- 7323)	2223 (1674- 2952)	7056 (5622- 8857)	1128 (615- 2068)	483 (243-961)	2483 (1567- 3933)
X	7548 (6443- 8843)	3511 (2935- 4201)	5363 (4523- 6359)	8153 (6718- 9894)	3113 (2553- 3797)	6287 (5515- 7166)	7 (4-13)	7 (4-12)	12 (6-21)
Y	2366 (1837- 3047)	1172 (892- 1539)	3189 (2701- 3766)	3010 (2491- 3638)	1387 (1129- 1703)	3267 (2801- 3810)	677 (392- 1168)	426 (252-721)	1194 (809- 1764)

Phase 2 Immunogenicity Conclusions

- Adjuvanted and non-adjuvanted formulations of NmCV-5 show similar immune responses at all timepoints.
- Menactra sero-response rates and GMTs are significantly improved following the 2nd dose.
- Some waning of immune responses is observed at 3 months post dose 1 with all groups.
- All subjects elicit high rSBA responses to the serogroups contained in the study vaccines after 2 doses.
- A single dose of NmCV-5 is better than 2 doses of Menactra for A, C, W and Y at 12-16 months of age.



Phase 3 study (2-29 YOs Africa)

۰

- Observer-blind, randomized, controlled study among healthy individuals at 2 sites: CVD Mali and MRC The Gambia; start August 2019.
- Total follow up 168 days post vaccination.
- 1800 subjects to be randomized as below:

Age Group	Number o	Vaccine	
19.20 маста	600	400	NmCV-5
18-29 years	600	200	Menactra®
11 17	600	400	NmCV-5
11-17 years	600	200	Menactra®
2.40	COO	400	NmCV-5
2-10 years	600	200	Menactra®

Phase 3 study (2-29 YOs Africa)

- Primary objectives:
 - Demonstrate NI of rSBA seroresponse* or GMTs to serogroups A, C, Y, and W of NmCV-5 compared to Menactra[®]
 - Demonstrate NI of rSBA seroresponse* or GMTs to serogroup X of NmCV-5 to the lowest immune response of Menactra[®]
- * Seroresponse is four fold rise in rSBA from baseline; NI margin 10 % for seroresponse and GMT ratio 0.5.
- Secondary Objectives:
 - To assess safety (Solicited reactions until Day 7, unsolicited AEs until Day 28, and SAEs until Day 168)
 - To assess other immune responses

(rSBA testing will be done at NeoMed Labs, Montreal, Canada)

Phase 3 study (18-85 y/o India)

- Observer-blind, randomized, controlled study among healthy individuals
- Total follow up 168 days post vaccination
- Multiple sites across India; study start October 2019.
- 1640 subjects will be randomized as below:

Age group	NmCV-5			Comparator (Menactra)
18-29 years	Lot 1	Lot 2	Lot 3	360
	360	360	360	500
30-60 years		75		25
61 – 85 years	years 75		25	

Phase 3 study (18-85 YOs India)

- Primary objectives:
 - Demonstrate lot-to-lot consistency (GMT ratios between 0.5 to 2.0) of 3 NmCV-5 lots.
 - Demonstrate non-inferiority (NI) of rSBA seroresponse * or GMTs to serogroups A, C, Y, & W for NmCV-5 compared to Menactra[®].
 - Demonstrate NI of rSBA seroresponse* or GMTs to serogroup X of NmCV-5 to the lowest immune response among four serogroups of Menactra.
- * Seroresponse is four fold rise in rSBA from baseline; NI margin 10 % for seroresponse & GMT ratio 0.5.
- Secondary Objectives:
 - To assess the safety (Solicited reactions until Day 7, unsolicited AEs until Day 28, and SAEs until Day 168)
 - To assess other immune responses

(rSBA testing will be done at NeoMed Labs, Montreal, Canada)

Phase 3 study (Infants, Africa)

- To be conducted among 9 month olds at 2 sites: Niger and Mali.
- Total follow up 168 days post vaccination.
- 1200 subjects will be randomized as below:


Cohort	9 months	15 months
1 (n=400)	NmCV-5 + MR + YF	DTP-Hib + Measles
2 (n=400)	DTP-Hib + MR + YF	NmCV-5 + Measles
3 (n=400)	DTP-Hib + MR + YF	Nimenrix + Measles

• All study vaccines (NmCV-5 and Nimenrix) will be given as a single intramuscular dose

Phase 3 study (Infants, Africa)

- Primary objectives:
 - Demonstrate NI of rSBA seroresponse* or GMTs to serogroups A, C, Y and W by a single dose of NmCV-5 compared to a single dose of Nimenrix[®] at 28 days.
 - Demonstrate NI of rSBA seroresponse* or GMTs to serogroup X of NmCV-5 to the lowest immune response among four serogroups of Nimenrix[®].
 - Demonstrate the immunological NI of EPI vaccines (MR, YF, M) when coadministered with NmCV-5 (at 9 or 15 months) compared to their coadministration with DTPHib (at 9 months)/Nimenrix[®] (at 15 months).
- * Seroresponse is four fold rise in rSBA from baseline; NI margin 10 % for seroresponse & GMT ratio 0.5.
- Secondary Objectives:
 - To assess safety (Solicited reactions till Day 7, unsolicited AEs until Day 28, and SAEs until Day 168)
 - To assess other immune response

NmCV-5 Clinical Development Plan



• Initial WHO PQ anticipated around Q2 2022.

How might a new polyvalent meningococcal be used in meningitis belt countries?

- As a stockpile vaccine to respond to CYWX epidemics
- As an EPI antigen to broaden protection against meningococci
- As a preventive vaccine to eliminate meningococcal epidemics
- Strategies may vary based on country-specific risk

Thank you!



Meningitis vaccine strategies using an ACYWX vaccine in Africa: Effects on epidemics and costs

Vaccine strategy		Effect on meningitis epidemics		Costs				
EPI vaccine (routine)	Catch up campaigns	Stockpile ACYWX CV (reactive campaigns)	Men A	Non A (CYWX)	Case mgmt. costs	Vaccine purchases	Reactive camp. costs	Surveillance costs
MenA CV	Finished	Yes	No epidemics	Non A epidemics continue	Yes	Birth cohort	Yes	Yes
ACYWX CV	No	Yes	No epidemics	Non A epidemics continue but may decr. in 10-15 years	Yes	Birth cohort	Yes	Yes
ACYWX CV	Yes (1-18 year olds)	Not necessary	No epidemics	Non A epidemics cease	None	Birth cohort & catch-up (1-18 yrs.)	None	Yes